IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase 3positiveIMDELLTRAIMFINZIPositive
AI Analysis
Summary
Amgen announced that IMDELLTRA in combination with IMFINZI met its Phase 3 DeLLphi-305 primary endpoint, demonstrating a highly significant overall survival benefit in first-line extensive stage small cell lung cancer versus durvalumab alone, with secondary endpoints for progression-free survival and objective response rate also met.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
DeLLphi-305 study demonstrated highly significant and clinically meaningful overall survival benefit for IMDELLTRA in combination with IMFINZI versus durvalumab alone. Study also met secondary endpoints for progression-free survival and objective response rate.
Importance:9/10
Sentiment:
0.95
oncologysmall cell lung cancercombination therapyoverall survival benefitPhase 3 positive
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 8, 2026 1:00 PM